Cargando…
Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders
The NLRP3 inflammasome has been implicated in the pathogenesis of a wide variety of human diseases. A few compounds have been developed to inhibit NLRP3 inflammasome activation, but compounds directly and specifically targeting NLRP3 are still not available, so it is unclear whether NLRP3 itself can...
Autores principales: | Jiang, Hua, He, Hongbin, Chen, Yun, Huang, Wei, Cheng, Jinbo, Ye, Jin, Wang, Aoli, Tao, Jinhui, Wang, Chao, Liu, Qingsong, Jin, Tengchuan, Jiang, Wei, Deng, Xianming, Zhou, Rongbin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679172/ https://www.ncbi.nlm.nih.gov/pubmed/29021150 http://dx.doi.org/10.1084/jem.20171419 |
Ejemplares similares
-
Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity
por: He, Hongbin, et al.
Publicado: (2018) -
Tranilast directly targets NLRP3 to treat inflammasome‐driven diseases
por: Huang, Yi, et al.
Publicado: (2018) -
Pharmacological Inhibitors of the NLRP3 Inflammasome
por: Zahid, Ayesha, et al.
Publicado: (2019) -
An RRx-001 Analogue With Potent Anti-NLRP3 Inflammasome Activity but Without High-Energy Nitro Functional Groups
por: Lin, Hualong, et al.
Publicado: (2022) -
Erianin: A Direct NLRP3 Inhibitor With Remarkable Anti-Inflammatory Activity
por: Zhang, Xinyong, et al.
Publicado: (2021)